Advertisement

Prostatic Cancer: Clinical Significance of Receptor Studies

  • G. D. Chisholm
  • T. Smith
  • F. K. Habib
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)

Abstract

In recent years, there has been a substantial increase in our knowledge about the mechanism of action of sex steroids in hormone responsive target organs. It is now believed that the high concentration of hormones measured in cells of organs such as breast, uterus and prostate is due to a binding (receptor) protein in the cytoplasm; this protein binds the appropriate hormones specifically and with a high affinity. Following the binding, the receptor protein undergoes a process known as activation — permitting or causing its translocation to the nucleus. Activation and translocation occur within minutes of the hormone entering the cell and the whole process has been shown to be energy dependent. Once within the nucleus, the hormone receptor forms a complex with the chromatin. This final step induces several responses characteristic of the steroid sensitive tissue and it should be noted that these processes are not manifested before the hormonal stimulation. This is, however, an over-simplification — since in some target tissues hormones entering the cell may also be subjected to metabolism (1).

Keywords

Androgen Receptor Progesterone Receptor Benign Prostatic Hyperplasia Steroid Receptor Human Prostatic Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    F.K. Habib, A.L. Tesdale, G.D. Chisholm, and A. Busuttil, Metabolic patterns in the epithelial and stromal components of benign prostatic hypertrophy, J.Endocr. 91 (1981) (In Press).Google Scholar
  2. 2.
    W.I.P. Mainwaring, “The Mechanism of Action of Androgens. Monographs on Endocrinology,” Springer Verlag, New York, Vol. 10 (1977).CrossRefGoogle Scholar
  3. 3.
    E.V. Jensen and E.R. Desombre, The diagnostic implications of steroid binding in malignant tissues, Adv. Clin. Chem. 19:57 (1977).PubMedCrossRefGoogle Scholar
  4. 4.
    G.D. Chisholm and F.K. Habib, Prostatic cancer: experimental and clinical advances, in: “Recent Advances in Urology/Andrology No. 3, W.F. Hendry, ed., Churchill Livingstone, Edinburgh (1981).Google Scholar
  5. 5.
    R.A. Cowan, B. Cook, S.K. Cowan, J.K. Grant, D.A.N Sirett, and A.M. Wallace, Testosterone 5α-reductase and the accumulation of dihydrotestosterone in benign prostatic hyperplasia, J.Steroid Biochem. 11:609 (1979).PubMedCrossRefGoogle Scholar
  6. 6.
    H.J. de Voogt and P.G. Dingjan, Is there a place for the assay of cytoplasms dual receptors in the endocrine treatment for prostatic cancer?, in “Steroid Receptors, Metabolism and Prostatic Cancer, F.H. Schröder and H.J. de Voogt, eds., Excerpta Medica, Amsterdam 265 (1980).Google Scholar
  7. 7.
    P. Ekman, M. Snochowski, A. Zetterberg, B. Hogberg, and J.A. Gustafsson, Steroid receptor content in human prostatic carcinoma and response to endocrine therapy, Cancer 44:1173 (1979).PubMedCrossRefGoogle Scholar
  8. 8.
    R. Ghanadian, G. Auf, B.J. Chaloner, and G.D. Chisholm, The use of methyltrienolone and the measurement of the free and bound cytoplasmic receptors for dihydrotestosterone in benign hypertrophied human prostate, J.Steroid Biochem. 9:325 (1978).PubMedCrossRefGoogle Scholar
  9. 9.
    M. Kreig, W. Bartsch, and K.D. Vogt, Binding metabolism and tissue level of androgens in human prostatic carcinoma, benign prostatic hyperplasia and normal prostate, in: “Steroid Receptors, Metabolism and Prostatic Cancer,” F.H. Schröder and H.J. de Voogt, eds., Excerpta Medica, Amsterdam, 102 (1980).Google Scholar
  10. 10.
    G.N. Lieskovsky and N. Bruchovsky, Assay of nuclear androgen receptor in human prostate, J. Urol. 121:54 (1979).PubMedGoogle Scholar
  11. 11.
    M. Menon, C.E. Tananis, L.L. Hicks, E.F. Hawkins, M.G. McLoughlin, and B.C. Walsh, Characterisation of the binding of a potent synthetic androgen methyltrienolone to human tissues, J. Clin. Invest. 61:150 (1978).PubMedCrossRefGoogle Scholar
  12. 12.
    B.G. Mobbs, I.E. Johnston, and J.G. Connolly, Androgen receptors and treatment of prostatic cancer, in: “Steroid Receptors, Metabolism and Prostatic Cancer,” F.H. Schröder and H.J. de Voogt, eds., Excerpta Medica, Amsterdam, 225 (1980).Google Scholar
  13. 13.
    S.A. Shain, R.W. Boesel, D.L. Lamm, and H.M. Radwin, Cytoplasmic and nuclear androgen receptor content of normal and neoplastic human prostates and lymph nodes metastases of human prostatic adenocarcinoma, J. Clin. Endocrinol. Metab. 50:704 (1980).PubMedCrossRefGoogle Scholar
  14. 14.
    D.A.N. Sirett and J.K. Grant, Androgen binding in cytosols and nuclei of human benign hyperplastic prostatic tissue, J. Endocr. 77:101 (1978).PubMedCrossRefGoogle Scholar
  15. 15.
    L.L. Hicks and P.C. Walsh, A microassay for the measurement of androgen receptors in human prostatic tissue, Steroids 33:2390 (1979).CrossRefGoogle Scholar
  16. 16.
    J.G. Lehoux, B. Benard and Elhilali, Dihydrotestosterone receptors in the human prostate. I. Nuclear concentration in normal, benign, and malignant tissues, Arch. Androl. 5:237 (1980).PubMedCrossRefGoogle Scholar
  17. 17.
    N. Bashirelahi, J.H. O’Toole, and J.D. Young, A specific 17 B-estradiol receptor in human benign hypertrophic prostate, Biochem. Med. 15:254 (1976).PubMedCrossRefGoogle Scholar
  18. 18.
    S.M. Sidh, J.D. Young, S.A. Karmi, J.R. Powder, and N. Bashirelahi, Adenocarcinoma of prostate: role of 17B-estradiol and 5α-dihydrotestosterone binding proteins, Urology 13:597 (1979).PubMedCrossRefGoogle Scholar
  19. 19.
    W.D. Tilley, D.D. Keightley, and V.R. Marshall, Oestrogen and progesterone receptors in benign prostatic hyperplasia in humans, J. Steroid Biochem. 13:395 (1980).PubMedCrossRefGoogle Scholar
  20. 20.
    N. Bruchovsky, P.S. Rennie, and P.R. Wilkin, New aspects of androgen action in prostatic cells: stromal localization of 5α-reductase, nuclear abundance of androstanolone and binding of receptor to linker deoxyribonucleic acid, in: “Steroid Receptors, Metabolism and Prostatic Cancer,” F.H. Schröder and H.J. de Voogt, eds., Excerpta Medica, Amsterdam, 57 (1980).Google Scholar
  21. 21.
    R.K. Wagner and K.H. Schultz, Clinical relevance of androgen receptor content in human prostatic carcinoma, Acta Endocrinologica 87:139 (1978).Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • G. D. Chisholm
    • 1
  • T. Smith
    • 1
  • F. K. Habib
    • 1
  1. 1.Western General HospitalEdinburghScotland

Personalised recommendations